Allery Treatment News

INEGY better than Crestor™ in Achieving Multiple "Goals" for LDL-Cholesterol & Other CHD Risk Factors in Hypercholesterolemia Patients

July 22, 2017

INEGY™ (ezetimibe/simvastatin) allowed significantly more patients with hypercholesterolemia than Crestor™(rosuvastatin) to achieve study specified levels ("Goals") for both Low Density Lipoprotein ("bad") cholesterol (LDL-C) and each one of the following coronary heart disease (CHD) risk factors: C-reactive protein (CRP), Apolipoprotein B (Apo B) or Non-HDL-cholesterol (non-HDL-C). This data was presented at the European Atherosclerosis Society (EAS 2007) meeting in Helsinki, Finland.1 The same study also showed that significantly more patients treated with INEGY attained the specified NECP ATP III** target of LDL-C Significantly more patients with triglyceride levels ≥200 mg/dL also achieved Non-HDL-C (